Janssen Pharmaceutica NV has identified bicyclic pyridin-2-one and pyrimidin-4-one derivatives acting as coagulation factor XIa inhibitors and thus reported to be useful for the treatment of thromboembolism, diabetes, diabetic retinopathy, septic shock, hereditary angioedema, arthritis, nephropathy and inflammatory disorders, among others.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a target protein binding moiety through a linker.
Researchers at Shanghai Institute of Materia Medica and the Wuhan Institute of Virology Chinese Academy of Sciences have prepared and tested cyclic bisbenzyl tetrahydroisoquinoline compounds reported to be useful for the treatment of fibrosis, viral infections and inflammatory disorders.
Daegu-Gyeongbuk Medical Innovation Foundation and Seoul National University Hospital have jointly developed adiponectin-derived peptoid derivatives reported to be useful for the treatment of skin inflammation, wound infection, alopecia, fibrosis, aging, skin wrinkling, cancer and metabolic diseases, among others.
Altamira Therapeutics Ltd. has entered into a collaboration and option agreement with Heqet Therapeutics srl, a spin-out from King’s College London, to utilize the company’s proprietary Oligophore delivery platform in cardiovascular research.
Lift Biosciences Ltd. has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof of concept using In-Lift, the company’s second-generation platform which is derived from iPSCs, has shown that the alpha neutrophil type cells produced from iPSCs are able to be activated by chemokines released by tumors and that the cells actively destroy cancer cells.
Propanc Biopharma Inc. has announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen via the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program with the Universities of Jaén and Granada.
Hepatocellular carcinoma (HCC) is the most frequent tumor of the liver, and in contrast to the reduction in the number of deaths in many common cancers, HCC’s mortality rates have gone up in recent years. One of the features that characterizes HCC is the activation of the Wnt/β-catenin signaling. Recent preclinical testing in HCC models has shown a reduction in tumor growth using siRNA or ASOs acting as β-catenin inhibitors.
RSS
